|
Back to Home » December 2022 News » Hansa Biopharma announces positive reimbursement decision in Italy for Idefirix® (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation |
Hansa Biopharma announces positive reimbursement decision in Italy for Idefirix® (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation |
December 08, 2022
Idefirix® is granted full access and reimbursement in line with the indication approved by the European Medicines Agency (EMA).1 The decision by the Italian Medicine Agency (AIFA) provides highly sensitized patients in Italy with the opportunity to receive Idefirix® to enable kidney...
Source URL: https://www.prnewswire.com:443/news-releases/hansa-biopharma-announces-positive-reimbursement-decision-in-italy-for-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-patients-in-kidney-transplantation-301697960.html
|
|
|
|
